Editing Management of Localized Prostate Cancer (section)

=== AUA ===

* '''[https://pubmed.ncbi.nlm.nih.gov/35536144/ 2022 AUA Guidelines on Clinically Localized Prostate Cancer]'''
** '''Individualized risk estimate of post-treatment prostate cancer recurrence should be provided to patients with prostate cancer'''
***Multiple predictive models and nomograms have been developed to estimate the risks of biochemical recurrence, metastases, and death from prostate cancer.
****See [https://www.mskcc.org/nomograms/prostate/post_op Memorial Sloan Keterring Cancer Center Post-Radical Prosatectomy Calculator]
**'''Specific intervals for PSA follow-up may be tailored to disease risk based on clinicopathologic features.'''
***'''Initial monitoring should in general be performed more frequently and is recommended every 3-6 months for the first 2 years after treatment.'''
***'''Subsequent monitoring between years 2 and 5 should occur every 6 months, with monitoring annually thereafter.'''
***'''The duration and interval of follow-up beyond 10 years for patients with an undetectable PSA at that time should be a shared decision''' based on patient disease risk, age, comorbidity status, and preference.
**Urinary, bowel, and sexual function should likewise be routinely evaluated, with the use of standardized/validated instruments recommended, in order to monitor the QOL impact from therapy.